APC-100 is an orally administered compound that acts as both an inhibitor of the androgen signaling pathways (i.e. serves as an androgen antagonist) as well as an anti-inflammatory molecule. Preclinical studies have demonstrated that APC-100 is effective in inhibiting prostate cancer tumor growth in vitro and in animal models of disease. In addition APC-100 was found to be safe and well tolerated. Phase 1 clinical studies in CRPC patients are currently ongoing. In 2006, APC-100 received a $4.5 million NCI RAPID Award as a first in first-in-class therapeutic oral drug for Castrate-Sensitive and Castrate-Resistant Prostate Cancer. The total funding received was approximately $8 million.